Fig. 7
From: Unearthing new genomic markers of drug response by improved measurement of discriminative power
Examples of new genomic markers for drugs with previously-proposedMANOVA markers. (Top) The mutational status of the CDKN2A gene is found to be the most discriminative marker for the approved drug Temsirolimus (MCC = 0.30 on the test set,), which was missed by the MANOVA test (PMANOVA = 9∙10− 3). (Bottom) The EWS_FLI1 translocation is found to be the most discriminative marker for the development drug BMS-754807 (MCC = 0.25 on the test set), which was also missed by the MANOVA test (PMANOVA = 0.01). While both tests are being applied to exactly the same data, only the chi-squared test could identify these confirmed false negatives of the MANOVA test